These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 36734188)
1. Activatable Fluorescent Probes Targeting Urokinase-Type Plasminogen Activator Receptor on the Cell Membrane. Kim TI; Cho S; Jin H; Bae J; Park C; Kim Y Chemistry; 2023 Apr; 29(23):e202203739. PubMed ID: 36734188 [TBL] [Abstract][Full Text] [Related]
2. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Ploug M; Ellis V; Danø K Biochemistry; 1994 Aug; 33(30):8991-7. PubMed ID: 8043585 [TBL] [Abstract][Full Text] [Related]
3. In vivo detection of urokinase-type plasminogen activator receptor (uPAR) expression in arterial atherogenesis using [ Khare HA; Døssing KBV; Ringgaard L; Christensen E; Urbak L; Sillesen H; Ripa RS; Binderup T; Pedersen SF; Kjaer A Atherosclerosis; 2022 Jul; 352():103-111. PubMed ID: 35396143 [TBL] [Abstract][Full Text] [Related]
6. Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET. Li ZB; Niu G; Wang H; He L; Yang L; Ploug M; Chen X Clin Cancer Res; 2008 Aug; 14(15):4758-66. PubMed ID: 18676745 [TBL] [Abstract][Full Text] [Related]
7. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. Persson M; Madsen J; Østergaard S; Jensen MM; Jørgensen JT; Juhl K; Lehmann C; Ploug M; Kjaer A J Nucl Med; 2012 Jan; 53(1):138-45. PubMed ID: 22213823 [TBL] [Abstract][Full Text] [Related]
8. Urokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapy. Li D; Liu S; Shan H; Conti P; Li Z Theranostics; 2013; 3(7):507-15. PubMed ID: 23843898 [TBL] [Abstract][Full Text] [Related]
9. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma. Persson M; Nedergaard MK; Brandt-Larsen M; Skovgaard D; Jørgensen JT; Michaelsen SR; Madsen J; Lassen U; Poulsen HS; Kjaer A J Nucl Med; 2016 Feb; 57(2):272-8. PubMed ID: 26429955 [TBL] [Abstract][Full Text] [Related]
10. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Plesner T; Behrendt N; Ploug M Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR). Liu D; Overbey D; Watkinson L; Giblin MF Bioconjug Chem; 2009 May; 20(5):888-94. PubMed ID: 19354275 [TBL] [Abstract][Full Text] [Related]
12. Self-assembled chitosan polymer intercalating peptide functionalized gold nanoparticles as nanoprobe for efficient imaging of urokinase plasminogen activator receptor in cancer diagnostics. Shahdeo D; Kesarwani V; Suhag D; Ahmed J; Alshehri SM; Gandhi S Carbohydr Polym; 2021 Aug; 266():118138. PubMed ID: 34044952 [TBL] [Abstract][Full Text] [Related]
13. A Cross Talk between Neuronal Urokinase-type Plasminogen Activator (uPA) and Astrocytic uPA Receptor (uPAR) Promotes Astrocytic Activation and Synaptic Recovery in the Ischemic Brain. Diaz A; Merino P; Manrique LG; Ospina JP; Cheng L; Wu F; Jeanneret V; Yepes M J Neurosci; 2017 Oct; 37(43):10310-10322. PubMed ID: 28931568 [TBL] [Abstract][Full Text] [Related]
14. Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105. Juhl K; Christensen A; Persson M; Ploug M; Kjaer A PLoS One; 2016; 11(2):e0147428. PubMed ID: 26828431 [TBL] [Abstract][Full Text] [Related]
15. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391 [TBL] [Abstract][Full Text] [Related]
16. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. Nykjaer A; Conese M; Christensen EI; Olson D; Cremona O; Gliemann J; Blasi F EMBO J; 1997 May; 16(10):2610-20. PubMed ID: 9184208 [TBL] [Abstract][Full Text] [Related]
17. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127 [TBL] [Abstract][Full Text] [Related]
18. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors. Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477 [TBL] [Abstract][Full Text] [Related]
19. Expression and localization of urokinase-type plasminogen activator receptor in bovine cumulus-oocyte complexes. García DC; Miceli DC; Rizo G; García EV; Valdecantos PA; Roldán-Olarte M Zygote; 2016 Apr; 24(2):230-5. PubMed ID: 25939353 [TBL] [Abstract][Full Text] [Related]
20. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]